Edition:
United States

MorphoSys AG (MORG.DE)

MORG.DE on Xetra

105.40EUR
25 Jun 2018
Change (% chg)

€0.50 (+0.48%)
Prev Close
€104.90
Open
€105.80
Day's High
€106.00
Day's Low
€105.40
Volume
7,246
Avg. Vol
114,067
52-wk High
€106.00
52-wk Low
€55.05

Chart for

About

MorphoSys AG develops and commercializes antibodies for therapeutic applications. The Company develops drugs using its own research and development, as well as in cooperation with pharmaceutical and biotechnology partners. The Company's operating segments include Proprietary Development and Partnered Discovery. In the Proprietar... (more)

Overall

Beta: 0.77
Market Cap(Mil.): €3,336.66
Shares Outstanding(Mil.): 31.81
Dividend: --
Yield (%): --

Financials

  MORG.DE Industry Sector
P/E (TTM): -- 248.83 34.14
EPS (TTM): -2.56 -- --
ROI: -19.51 -5.25 13.10
ROE: -20.01 -6.83 15.09

German stocks - Factors to watch on June 13

FRANKFURT/BERLIN, June 13 The following are some of the factors that may move German stocks on Wednesday:

Jun 13 2018

German stocks - Factors to watch on May 17

BERLIN/FRANKFURT, May 17 The following are some of the factors that may move German stocks on Thursday:

May 17 2018

BRIEF-Morphosys AG Reports Q1 Revenue Of 2.8 Million EUR

* Q1 REVENUE 2.8 MILLION EUR VERSUS 11.8 MILLION EUR YEAR AGO

May 02 2018

BRIEF-Morphosys, Galapagos initiate IGUANA phase 2 clinical trial with Mor106 in Atopic Dermatitis patients

* DGAP-NEWS: MORPHOSYS AND GALAPAGOS ANNOUNCE INITIATION OF THE IGUANA PHASE 2 CLINICAL TRIAL WITH MOR106 IN ATOPIC DERMATITIS PATIENTS

May 01 2018

BRIEF-MorphoSys Announces Approval Of Tremfya(R)In South Korea

* DGAP-NEWS: MORPHOSYS ANNOUNCES APPROVAL OF TREMFYA(R) (GUSELKUMAB) IN SOUTH KOREA

Apr 26 2018

BRIEF-Morphosys Says NASDAQ IPO Leads To Total Gross Proceeds Of USD 239 Million

* DGAP-NEWS: MORPHOSYS ANNOUNCES CLOSING OF NASDAQ IPO THROUGH AN ADS OFFERING AND EXERCISE OF THE UNDERWRITERS' OPTION TO PURCHASE ADDITIONAL ADSS, LEADING TO TOTAL GROSS PROCEEDS OF USD 239 MILLION

Apr 23 2018

BRIEF-Morphosys Announces Pricing Of IPO Of American Depositary Shares On Nasdaq

* MORPHOSYS ANNOUNCES PRICING OF INITIAL PUBLIC OFFERING OF AMERICAN DEPOSITARY SHARES (ADSS) ON NASDAQ

Apr 18 2018

BRIEF-Morphosys to increase capital to implement Offering Of 8.3 mln ADS

* DGAP-ADHOC: MORPHOSYS RESOLVES A CAPITAL INCREASE TO IMPLEMENT THE OFFERING OF 8,300,000 AMERICAN DEPOSITARY SHARES (ADS) IN THE UNITED STATES

Apr 17 2018

BRIEF-Morphosys AG Sees U.S. IPO 8.3 Mln American Depositary Shares - SEC Filing

* MORPHOSYS AG SEES U.S. IPO 8.3 MLN AMERICAN DEPOSITARY SHARES - SEC FILING

Apr 09 2018

BRIEF-Morphosys Says Tremfya Approved To Treat Psoriasis In Japan

* SAYS ANNOUNCES APPROVAL OF TREMFYA(R) (GUSELKUMAB) FOR THE TREATMENT OF MODERATE TO SEVERE FORMS OF PSORIASIS AND PSORIATIC ARTHRITIS IN JAPAN Source text for Eikon: Further company coverage:

Apr 06 2018

Earnings vs. Estimates